← All trials
NCT03477422
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 11, 2014
- Primary completion
- May 8, 2017
- Completion date
- May 8, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Venus Remedies LtdLead sponsor
- Ajanta Hospital and Research CentreOverall official - principal investigator
- All India Institute of Medical SciencesOverall official - principal investigator
- Christian Medical College, Vellore, IndiaOverall official - principal investigator
- Deenanath Mangeshkar Hospital & Research CentreOverall official - principal investigator
- Aligarh Muslim UniversityOverall official - principal investigator
- King George's Medical UniversityOverall official - principal investigator
- K.L.E.S Dr. Prabhakar Kore Hospital & Medical research CentreOverall official - principal investigator
- MV Hospital and Research CenterOverall official - principal investigator
- Om Surgical Centre and Maternity HomeOverall official - principal investigator
- Postgraduate Institute of Medical Education and ResearchOverall official - principal investigator
- Sapthagiri Institute of Medical Sciences and Research Center (SIMSRC)Overall official - principal investigator
- Sir Ganga Ram HospitalOverall official - principal investigator
- Sher-i-Kashmir Institute of Medical Sciences (SKIMS)Overall official - principal investigator
- SP Medical College, BikanerOverall official - principal investigator
- Trimurti HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.